ALX Oncology (ALXO) CEO logs RSU tax-related share disposition

Rhea-AI Filing Summary

ALX Oncology Holdings CEO Jason Lettmann reported a routine tax-related share withholding. On the RSU vesting date, 2,201 shares of common stock were withheld at $2.27 per share to cover his tax liability, a non‑market disposition. Following this, he directly owns 305,920 shares, which include 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		F(1)		2,201	D	$2.27	305,920(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

2. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025.

	/s/ Shelly Pinto, by power of attorney	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ALX Oncology (ALXO) CEO Jason Lettmann report?

ALX Oncology CEO Jason Lettmann reported a tax-related share disposition, not an open-market trade. 2,201 common shares were withheld to satisfy his tax liability triggered by vesting restricted stock units, a standard administrative event rather than a discretionary buy or sell decision.

How many ALXO shares were disposed of and at what price in this Form 4?

A total of 2,201 ALX Oncology common shares were withheld at $2.27 per share. The disposition was coded “F,” meaning shares were delivered to cover taxes owed upon RSU vesting, rather than sold on the open market for investment or portfolio reasons.

How many ALXO shares does CEO Jason Lettmann own after the reported transaction?

After the tax-withholding disposition, Jason Lettmann directly owns 305,920 ALX Oncology common shares. This total includes 3,000 shares he acquired through the company’s employee stock purchase plan on December 31, 2025, as noted in the filing footnotes.

Was the ALXO CEO’s Form 4 transaction an open-market sale of shares?

The transaction was not an open-market sale. It was a Form 4 code “F” event, where 2,201 shares were withheld by the issuer to pay Jason Lettmann’s tax liability associated with vesting RSUs, a common administrative method of handling equity compensation taxes.

What role did restricted stock units (RSUs) play in this ALXO insider filing?

The filing shows RSUs vesting triggered the transaction. When Jason Lettmann’s RSUs vested, 2,201 underlying shares were withheld to cover his tax obligation. This mechanism lets the company satisfy withholding requirements without the executive arranging a separate cash payment.

What additional share acquisition by the ALXO CEO is disclosed in the footnotes?

The footnotes state Jason Lettmann’s holdings include 3,000 shares acquired under ALX Oncology’s employee stock purchase plan on December 31, 2025. These shares form part of his 305,920 directly owned shares reported after the tax-withholding disposition transaction.